NEW YORK (Reuters Health) - The finding comes from the “Double-Diamond” study, a multicenter, randomized, double-blind, placebo-controlled, 2-way, 2-attack, crossover study. Included in the 12-week study were 248 adolescent patients (ages 12 to 17 years) with an established diagnosis of migraine, with or without aura.Dr. Donald W. Lewis, of Eastern Virginia Medical School, Norfolk, and colleagues explain that a single-blind “placebo challenge” was used for each migraine attack. If a headache response to the initial placebo treatment was achieved at 15 minutes, no additional medications were given. If migraine intensity remained moderate or severe, the patients were then treated with 5 mg zolmitriptan nasal spray or placebo according to a randomized crossover schedule.
